Urinary Tract infection (UTI) is one of the most common infections worldwide, patients present to multiple different specialities in the community, primary and secondary care. Antibiotics are considered standard first line therapy in the treatment of urinary tract infections, however there is an alarming rise in global antibiotic resistance rates, so much so that the World Health Organisation has labelled antibiotic resistance as one of the biggest challenges to public health in our lifetime, publishing a global action plan to tackle this challenge. As a result, there is an increasing need to discover non-antibiotic alternatives, recently a number of novel therapies have been introduced into clinical practice. These are divided into oral, topical, intravesical and immunomodulation therapies. The aim of this paper is to summarise the current non-antibiotic treatments as a practical guide to utilise in patient care.
ButlerCCHawkingMKQuigleyA, et al. Incidence, severity, help seeking, and management of uncomplicated urinary tract infection: a population-based survey. Br J Gen Pract2015; 65: e702–e707.
KlevensRMEdwardsJRRichardsClJr, et al. Estimating health care-associated infections and deaths in U.S. Hospitals, 2002. Public Health Rep2007; 122: 160–166.
5.
ScottR. The direct medical costs of healthcare-associated infections in US hospitals and the benefits of prevention, https://stacks.cdc.gov/view/cdc/11550 (2009, accessed 27 June 2023).
6.
LumsdenLHynerGC. Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients. Women Health1985; 10: 79–86.
7.
HootonTMVecchioMIrozA, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med2018; 178: 1509–1515.
8.
HootonTMScholesDHughesJP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med1996; 335: 468–474.
9.
AdattoKDoebeleKGGallandL, et al. Behavioral factors and urinary tract infection. JAMA1979; 241: 2525–2526.
10.
LemaVM. Urinary tract infection in young healthy women following heterosexual anal intercourse: case reports. Afr J Reprod Health2015; 19: 134–139.
11.
GuptaKHillierSHootonT, et al. Effects of contraceptive method on the vaginal microbial flora: a prospective evaluation. J Infect Dis2000; 181: 595–601.
12.
Luís DominguesFPereiraL. Can Cranberries contribute to reduce the incidence of urinary tract infections? A systematic review with meta-analysis and trial sequential analysis of clinical trials. J Urol2017; 198: 614–621.
13.
LiskaDJKernHJMakiKC. Cranberries and urinary tract infections: how can the same evidence lead to conflicting advice?Adv Nutr2016; 7: 498–506.
14.
MenaPGonzález de LlanoDBrindaniN, et al. 5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone and its sulphate conjugates, representative circulating metabolites of flavan-3-ols, exhibit anti-adhesive activity against uropathogenic Escherichia coli in bladder epithelial cells. J Funct Foods2017; 29: 275–280.
GbinigieOASpencerEAHeneghanCJ, et al. Cranberry extract for symptoms of acute, uncomplicated urinary tract infection: a systematic review. Antibiotics2020; 10: 1–14.
17.
TambunanMPRahardjoHE. Cranberries for women with recurrent urinary tract infection: a meta-analysis. Med J Indones2019; 28: 268–275.
18.
BouckaertJBerglundJSchembriM, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol2005; 55: 441–455.
19.
KranjčecBPapešDAltaracS. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol2014; 32: 79–84.
20.
LengerSMBradleyMSThomasDA, et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol2020; 223: 265.e1–265.e13.
21.
KranzJSchmidtSSchneidewindL. Current evidence on nonantibiotic prevention of recurrent urinary tract infections. Eur Urol Focus2019; 5: 17–19.
22.
FranssenMCookJRobinsonJ, et al. D-MannosE to prevent Recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial. BMJ Open2021; 11: e037128.
23.
LeeBSBhutaTSimpsonJM, et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev2012; 10: CD003265.
24.
BakhitMKrzyzaniakNHilderJ, et al. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. Br J Gen Pract2021; 71: E528–E537.
25.
BotrosCLozoSIyerS, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. Int Urogynecol J2022; 33: 571–580.
26.
KashourisEG. ALTAR trial of antibiotic alternative in recurrent urinary infection is a step towards a more collective conversation. BMJ2022; 377: o914.
27.
HicklingDRNittiVW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol2013; 15: 41–48.
CribbySTaylorMReidG. Vaginal microbiota and the use of probiotics. Interdiscip Perspect Infect Dis2008; 2008: 256490–256499.
30.
FalagasMEBetsiGITokasT, et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs2006; 66: 1253–1261.
31.
NgQXPetersCVenkatanarayananN, et al. Use of Lactobacillus spp. To prevent recurrent urinary tract infections in females. Med Hypotheses2018; 114: 49–54.
32.
AntoniouVSomaniBK. Topical and oral oestrogen for recurrent urinary tract infection-evidence-based review of literature, treatment recommendations, and correlation with the European Association of Urology Guidelines on urological infections. Eur Urol Focus2022; 8: 1768–1774.
33.
KirkengenALAndersenPGjersøeE, et al. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scand J Prim Health Care1992; 10: 139–142.
GialerakiAValsamiSPittarasT, et al. Oral contraceptives and HRT risk of thrombosis. Clin Appl Thromb Hemost2018; 24: 217–225.
36.
De VitaDGiordanoS. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J2012; 23: 1707–1713.
37.
GoddardJCJanssenDAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J2018; 29: 933–942.
38.
DamianoRQuartoGBavaI, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol2011; 59: 645–651.
39.
AziminiaNHadjipavlouMPhilippouY, et al. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int2019; 123: 753–768.
40.
PrattleySGeraghtyRMooreM, et al. Role of vaccines for recurrent urinary tract infections: a systematic review. Eur Urol Focus2020; 6: 593–604.
41.
BrodieAEl-TajiOJourI, et al. A retrospective study of immunotherapy treatment with Uro-Vaxom (OM-89®) for prophylaxis of recurrent urinary tract infections. Curr Urol2020; 14: 130–134.
42.
NickelJCSaz-LealPDoironRC. Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future. Can Urol Assoc J2020; 14: 281–287.
43.
Lorenzo-GómezMFPadilla-FernándezBGarcía-CriadoMB, et al. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections. Front Cell Infect Microbiol2015; 5: 50.
44.
Lorenzo-GómezMFPadilla-FernándezBGarcía-CriadoFJ, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J2013; 24: 127–134.
45.
YangBFoleyS. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune®. BJU Int2018; 121: 289–292.
46.
Lorenzo-G OmezFFoleySCurtis NickelJ, et al. Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evid. Epub ahead of print 21 January 2022. DOI: 10.1056/EVIDOA2100018
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
